UltraCol, which was created with the unique technology of biomedical beauty group UltraV (CEO Kwon Kwon-jin), announced on the 7th that it had obtained product approval from The Philippines FDA.

As of 2021, the Philippine medical device market was about $777 million, with an average annual growth of 8.8% due to the increase in population and elderly population and increased medical expenditure.The Philippine medical device market relies on imports of most high value-added medical devices due to a lack of its own technology.

Therefore, import growth in the sector is expected to continue in the future.

In general, it is known that it takes about three years to obtain an item license in the Philippines, but UltraV introduced that the period could be drastically shortened based on related know-how such as preparing submission documents necessary for permission.

​The product license will officially be exported to the Philippines through the Philippine agency Skinmedicine, and as local clinics can import more quantities, it plans to introduce the excellence of UltraCol to the Philippines and actively expand its market share through this.

​"As the Philippines is a country that forms a large beauty and medical market among major Southeast Asian countries, we will quickly expand our market share in the region based on the competitiveness of UltraCol," an UltraV official said. "We will also make various efforts to become a global ultra-class company by strengthening our influence in the existing market and accelerating our entry into the untapped overseas market."

​An official from UltraV said, "The 4th generation of self-collagen dermabooster 'UltraCol' consists of the same PDO as the melting thread, which promotes the production of self-collagen without the burden of remaining in the body. It can be injected directly into the skin with a fourth-grade medical device license to expect fast and high effects, and it is composed of uniform and smooth micro-spherical particles to alleviate tissue damage around the skin."

In fact, clinical results show that the wrinkle index decreased and the luminous index and dermal density increased after 8 weeks of using UltraCol

In addition, UltraV won the IR52 Jang Young-sil Award in 2020 in recognition of the excellence of the world's first PDO material filler manufacturing and mass production technology, and has a history of winning the Korean Patent Grand Prize, as well as KFDA certification from the Ministry of Food and Drug Safety in Korea and CE certification in Europe.

​Meanwhile, "UltraCol" has recently obtained product licenses from the Thai Food and Drug Administration (TFDA) and obtained sales license certification in a number of countries. It also explains that it is now visible to enter untapped Asian markets such as China and Russia.

​

​

​